MASON, Ohio --(BUSINESS WIRE)--Oct. 8, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2019 financial results on Wednesday, October 30, 2019
Clinical evidence demonstrates that AtriClip ® devices exclude and electrically isolate the left atrial appendage MASON, Ohio --(BUSINESS WIRE)--Aug. 27, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage (LAA)
MASON, Ohio --(BUSINESS WIRE)--Aug. 26, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Morgan Stanley 17 th Annual Global
MASON, Ohio --(BUSINESS WIRE)--Aug. 13, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc.
MASON, Ohio --(BUSINESS WIRE)--Aug. 13, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc.
Acquisition Expands Addressable Market Opportunity and Complements Offerings for the Treatment of Atrial Fibrillation Announces Updates to 2019 Outlook Conference Call Monday, August 12 th at 8:30am ET MASON, Ohio --(BUSINESS WIRE)--Aug. 12, 2019-- AtriCure, Inc.
Acquisition Expands Addressable Market Opportunity and Complements Offerings for the Treatment of Atrial Fibrillation Announces Updates to 2019 Outlook Conference Call Monday, August 12 th at 8:30am ET MASON, Ohio --(BUSINESS WIRE)--Aug. 12, 2019-- AtriCure, Inc.
